Vane, J R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971; 231:232–5.CrossRefGoogle ScholarPubMed

Evangelista, V, Manarini, S, Di Santo, A, et al. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. Circ Res. 1998; 593–5.CrossRefGoogle Scholar

Bjornsson, T D, Schneider, D E, Berger, H. Aspirin aetylates fibrinogen and enhances fibrinolysis. Fibrinolytic effect is independent of changes in plasminogen activator levels. J Pharmacol Exp Ther. 1989; 250:154–61.Google ScholarPubMed

De Schryver, E L L M, van Gijn, J, Kappelle, L J, Koudstaal, P J, Algra, A. Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke. J Neurol. 2005;252:1316–21.CrossRefGoogle ScholarPubMed

Kovich, O, Clark, C O. Thrombotic complications related to discontinuation of warfarin and aspirin therapy perioperatively for cutaneous operation. J Am Acad Dermatol. 2003; 48:233–7.CrossRefGoogle ScholarPubMed

Sibon, I, Orgogozo, J-M. Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology. 2004; 62:1187–9.Google Scholar

Maulaz, A B, Bezerra, D C, Michel, P, Bogousslavsky, J. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol. 2005; 62:1217–20.CrossRefGoogle Scholar

Broderick, J P, Bonomo, J B, Kissela, B M, et al. Withdrawal of antithrombotic agents and its impact on ischemic stroke occurrence. Stroke. 2011; 42:2509–14.CrossRefGoogle ScholarPubMed

Watanabe, H, Morimoto, T, Natsuaki, M, et al. Antiplatelet therapy discontinuation and the risk of serious cardiovascular events after coronary stenting: Observations from the CREDO-Kyoto Registry Cohort-2. PLoS One. 2015; 10(4):e0124314.Google Scholar

Rossini, R, Musumeci, G, Capodanno, D, et al. Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry. Thromb Haemost. 2015; 113(2):272–82.Google Scholar

Burger, W, Chemnitius, J M, Kneissl, G D, Rücker, G. Low-dose aspirin for secondary cardiovascular prevention – cardiovascular risks ater its perioperative withdrawal versus bleed risks with its continuation – review and meta-analysis. J Int Med. 2005; 257:399–414.Google Scholar

García Rodríguez, L A, Soriano, L C, Hill, C, Johansson, S. Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study. Neurology. 2011; 76:740–6.Google Scholar

Weimar, C, Cotton, D, Sha, N, et al. Discontinuation of antiplatelet study medication and risk of recurrent stroke and cardiovascular events: results from the PRoFESS study. Cerebrovasc Dis. 2013; 35:538–43.CrossRefGoogle ScholarPubMed

Lee, J, Kim, J K, Kim, J H, et al. Recovery time of platelet function after aspirin withdrawal. Curr Ther Res Clin Exp. 2014; 76:26–31.Google Scholar

Le Manach, Y, Kahn, D, Bachelot-Loza, C, et al. Impact of aspirin and clopidogrel interruption on platelet function in patients undergoing major vascular surgery. PLoS One. 2014; 9(8):e104491.Google Scholar

Aguejouf, O, Belougne-Malfatti, E, Doutremepuich, F, Belon, P, Doutremepuich, C. Thromboembolic complications several days after a single-dose administration of aspirin. Thromb Res. 1998; 89(3):123–7.Google Scholar

Doutremepuich, C, Aguejouf, O, Eizayaga, F X, Desplat, V. Reverse effect of aspirin: is the prothrombotic effect after aspirin discontinuation mediated by cyclooxygenase 2 inhibition? Pathophysiol Haemost Thromb. 2007; 36:40–4.CrossRefGoogle ScholarPubMed

Aguejouf, O, Eizayaga, F, Desplat, V, Belon, P, Doutremepuich, C. Prothrombotic and hemorrhagic effects of aspirin. Clin Appl Thromb Hemost. 2009; 15(5):523–8.Google Scholar

Vial, J H, McLeod, L J, Roberts, M S. Rebound elevation in urinary thromboxane B2 and 6-keto-PGF1 alpha excretion after aspirin withdrawal. Adv Prostatglandin Thromboxane Leukot Res. 1991; 21:157–60.Google Scholar

Moussa, S A, Forsythe, M S, Bozarth, J M, Reilly, T M. Effect of single oral dose of aspirin on human platelet functions and plasma plasminogen activator inhibitor-1. Cardiology. 1993; 83:367–73.Google Scholar

Armstrong, M J, Gronseth, G, Anderson, D C, et al. Summary of evidence-based guideline: Periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: Report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2013; 80:2065–9.Google Scholar

Mantz, J, Samama, C M, Tubach, F, et al. Impact of preoperative maintenance or interruption of aspirin on thrombotic and bleeding events after elective non-cardiac surgery: The multicentre, randomized, blinded, placebo-controlled, STRATAGEM trial. Br J Anaesth. 2011; 107(6):899–910.Google Scholar

Dorsam, R T, Kunapuli, S P. Central role of the P2Y12 receptor in platelet activation. J Clin Invest. 2004; 113(3):340–5.CrossRefGoogle ScholarPubMed

CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996; 348(9038):1329–39.Google Scholar

Diehl, P, Halscheid, C, Olivier, C, et al. Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessation. Clin Res Cardiol. 2011; 100:765–71.Google Scholar

Sambu, N, Warner, T, Curzen, N. Clopidogrel withdrawal: is there a “rebound” phenomenon? Thromb Haemost. 2011; 105:211–20.CrossRefGoogle Scholar

Collet, J-P, Montalescot, G, Steg, P G, et al. Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial. Arch Cardiovasc Dis. 2009; 102:485–96.Google Scholar

Geraghty, O C, Paul, N L M, Chandratheva, A, Rothwell, P M. Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke. Neurology. 2010; 74:1891–6.Google Scholar

Ford, I, Scott, N W, Herd, V, et al. A randomized controlled trial of platelet activity before and after cessation of clopidogrel therapy in patients with stable cardiovascular disease. J Am Coll Cardiol. 2014; 63:233–9.CrossRefGoogle ScholarPubMed

Rossen, J D, Chalouhi, N, Wassef, S N, et al. Incidence of cerebral ischemic events after discontinuation of clopidogrel in patients with intracranial aneurysms treated with stent-assisted techniques. J Neurosurg. 2012; 117:929–33.Google Scholar

Fiedler, A K, Mehilli, J, Kufner, S, et al. Randomised, double-blind trial on the value of tapered discontinuation of clopidogrel maintenance therapy after drug-eluting stent implantation. Thromb Haemost. 2014; 111:1041–9.Google Scholar

Mauri, L, Kereiakes, D J, Yeh, R W, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;Nov 16 (Epub ahead of print).CrossRefGoogle Scholar

Vongpatanasin, W, Hillis, L D, Lange, R A. Prosthetic heart valves. N Engl J Med. 1996; 335:407–16.Google Scholar

The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Guidelines for the management of atrial fibrillation. Eur Heart J. 2010; 31:2369–429.Google Scholar

Douketis, J D, Berger, P B, Dunn, A S, et al. The perioperative management of antithrombotic therapy. American College of Chest Physicians evidence-based clinicial practice guidelines (8th edition). Chest. 2008; 133:299–339S.Google Scholar

Di Biase, L, Burkhardt, J D, Santangeli, P, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management. Results from the role of coumadin in preventing thromboembolism in atrial fibrillation patients undergoing catheter ablation (COMPARE) randomized trial. Circulation. 2014; 129:2638–44.Google Scholar

Fang, M C, Go, A S, Chang, Y, Borowsky, L H, et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010; 3:624–31.Google Scholar

Tulner, L R, Van Campen, J P C M, Kuper, I M J A, et al. Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation. A prospective, descriptive study. Drugs Aging. 2010; 27(1):39–50.Google Scholar

Blacker, D J, Wijdicks, E F M, McClelland, R L. Stroke risk in anticoagulated patients with atrial fibrillation. Neurology. 2003; 61:964–8.Google Scholar

Raunsø, J, Selmer, C, Olesen, J B, et al. Increased short-term riks of thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation. Eur Heart J. 2012; 33(15):1886–92.CrossRefGoogle ScholarPubMed

Di Biase, L, Gaita, F, Toso, E, et al. Does periprocedural anticoagulation management of atrial fibrillation affect the prevalence of silent thromboembolic lesion detected by diffusion cerebral magnetic resonance imaging in patients undergoing radiofrequency atrial fibrillation ablation with open irrigated catheters? Results from a prospective multicenter study. Heart Rhythm. 2014; 11(5):791–8.Google Scholar

Garcia, D A, Regan, S, Henault, L E, et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med. 2008; 168(1):63–9.Google Scholar

Cundiff, D K. Clinical evidence for rebound hypercoagulability after discontinuing oral anticoagulants for venous thromboembolism. Medscape J Med. 2008; 10(11):258.Google Scholar

Genewein, U, Haeberli, A, Straub, P W, Beer, J H. Rebound after cessation of oral anticoagulant therapy: The biochemical evidence. Br J Haematol. 1996;92:479–85.CrossRefGoogle ScholarPubMed

Reddy, V Y, Sievert, H, Halperin, J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: A randomized clinical trial. JAMA. 2014; 312(19):1988–98.Google Scholar

Bai, R, Horton, R P, Di Biase, L, et al. Intraprocedural and long-term incomplete occlusion of the left atrial appendage following placement of the Watchman device: A single center experience. J Cardiovasc Electrophysiol. 2012; 23(5):455–61.Google Scholar

Chatterjee, S, Sardar, P, Giri, J S, Ghosh, J, Mukherjee, D. Treatment discontinuations with new oral agents for long-term anticoagulation: Insights from a meta-analysis of 18 randomized trials including 101,801 patients. Mayo Clin Proc. 2014; 89(7):896–907.Google Scholar

Zalesak, M, Siu, K, Francis, K, et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes. 2013; 6(5):567–74.CrossRefGoogle ScholarPubMed

Nascimento, T, Birnie, D H, Healey, J S, et al. Managing novel oral anticoagulants in patients with atrial fibrillation undergoing device surgery: Canadian survey. Can J Cardiol. 2014; 30(2):231–6.CrossRefGoogle ScholarPubMed

Watanabe, M, Siddiqui, F M, Qureshi, A I. Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment. Neurocrit Care. 2012; 16:203–9.Google Scholar

Patel, M R, Hellkamp, A S, Lokhnygina, Y, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: Analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol. 2013; 61(6):651–8.Google Scholar

Reynolds, M R. Discontinuation of rivaroxaban: Filling in the gaps. J Am Coll Cardiol. 2013;61(6):659–60.Google Scholar

Granger, C B, Alexander, J H, McMurray, J J, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11):981–92.CrossRefGoogle ScholarPubMed

Granger, C B, Lopes, R D, Hanna, M, et al. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Am Heart J. 2015; 169(1):25–30.Google Scholar

Connolly, S J, Ezekowitz, M D, Yusuf, S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12):1139–51.Google Scholar

Giugliano, R P, Ruff, C T, Braunwald, E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22):2093–104.Google Scholar

Davignon, J, Leiter, L A. Ongoing clinical trials of the pleiotropic effects of statins. Vasc Health Risk Manag. 2005; 1(1):29–40.Google Scholar

Amarenco, P, Bogousslavsky, J, Callahan, A, et al. High-dose atorvastatin after stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) investigators. N Eng J Med. 2006; 355:549–59.Google Scholar

Colvicchi, F, Bassi, A Santini, M, Caltagirone, C. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke. 2007; 38:2652–7.Google Scholar

Blanco, M, Nombela, F, Castellanos, M, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology. 2007; 69:904–10.Google Scholar

Fuentes, B, Martínez-Sánchez, P, Díez-Tejedor, E. Lipid-lowering drugs in ischemic stroke prevention and their influence on acute stroke outcome. Cerebrovasc Dis. 2009; 27(1):126–33.Google Scholar

Endres, M. Statins and stroke. J Cereb Blood Flow Metab. 2005; 25(9):1093–110.Google Scholar

Li, J-J, Li, Y-S, Chu, J-M, et al. Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia. Clinica Chimica Acta. 2006; 366:269–73.Google Scholar

Rosengarten, B, Auch, D, Kaps, M. Effects of initiation and acute withdrawal of statins on the neurovascular coupling mechanism in healthy, normocholesterolemic humans. Stroke. 2007; 38:3193–7.Google Scholar

Dowlatshahi, D, Demchuk, A M, Fang, J, et al. Association of statins and statin discontinuation with poor outcome and survival after intracerebral hemorrhage. Stroke. 2012; 43:1518–23.Google Scholar

Robinson, T G, Potter, J F, Ford, G A, et al. Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): A prospective, randomised, open, blinded-endpoint trial. Lancet Neurol. 2010; 9(8):767–75.Google Scholar

Bath, et al. Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): A partial-factorial randomised controlled trial. Lancet. 2014; 22 October: Epub ahead of print.Google Scholar

Baird, T A, Parsons, M W, Phan, T, et al. Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. Stroke. 2003; 34:2208–14.CrossRefGoogle ScholarPubMed

Rosso, C, Corvol, J C, Pires, C, et al. Intensive versus subcutaneous insulin in patients with hyperacute stroke: Results from the randomized INSULINFARCT trial. Stroke. 2012; 43(9):2343–9.Google Scholar